As communities across the U.S. have struggled to cope with the effects of the COVID-19 pandemic, many have focused on the lack of widespread testing as a major barrier to safely reopening the country.
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
Every major medical center in America sits on a gold mine of patient data that could be worth millions of dollars to companies that could use it to develop new treatments and technologies. A new framework could help them do so more responsibly, going beyond the minimum legal requirements and respecting patients by giving them more say in how their individual data may be used.
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.
When seizures last longer than about 5 minutes--a condition called status epilepticus--emergency treatment is required. About two-thirds of people respond to initial treatment with benzodiazepines, but the others need a second drug. Which drug to choose is a matter of some debate.
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
In a study published today (May 13, 2020) in the New England Journal of Medicine, scientists in the U.S. and Japan report that in the laboratory, cats can readily become infected with SARS-CoV-2, the virus that causes COVID-19, and may be able to pass the virus to other cats.
A study from Washington University School of Medicine in St. Louis has found that stroke evaluations fell by nearly 40% during a period of the COVID-19 pandemic, suggesting that many stroke patients are not seeking potentially life-saving medical treatment.
In one of the first reported cases of its kind, a 3-week-old infant in critical condition recovered from COVID-19 due to rapid recognition and treatment by physicians from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). The case was published April 22 in the New England Journal of Medicine.
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.
In a New England Journal of Medicine "Perspective" published today, Wafaa El-Sadr, MD, MPH, global director of ICAP at Columbia University Mailman School of Public Health, and Jessica Justman, MD, ICAP's senior technical director, and associate professor of epidemiology, urge a coordinated global effort in the face of the COVID-19 pandemic, with "countries around the world [taking] concrete steps to assist Africa in staying ahead of the curve, even as they confront their own epidemics."
In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Jonathan Grein, MD, director of Hospital Epidemiology at Cedars-Sinai.
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma. Study showed 93% of patients responded with 67% achieving complete response.
Areas of Harris County, Texas, where residents are most at risk for hospitalization and critical care needs due to COVID-19 have been mapped for the first time by researchers at The University of Texas Health Science Center of Houston (UTHealth).
Researchers from the University of California, Irvine have conducted a statistical analysis that predicts more than 70,000 heart attacks, strokes and other adverse cardiovascular events could be prevented each year in the U.S. through the use of a highly purified fish oil therapy.
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study from National Institutes of Health, CDC, UCLA and Princeton University scientists The New England Journal of Medicine.
Using a combination of magnetic resonance imaging (MRI) to target and sample suspicious prostate tissue, along with a standard prostate biopsy, is significantly more likely to detect the most aggressive prostate cancers than standard biopsy alone. This finding, published today in the New England Journal of Medicine, could allow a higher percentage of prostate cancer patients to avoid unnecessary treatment for slow-growing prostate cancers that are not likely to spread.
The emergence and rapid increase in cases of coronavirus disease 2019 (COVID-19), a respiratory illness caused by a novel coronavirus, pose complex challenges to the global public health, research and medical communities, write federal scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and from the Centers for Disease Control and Prevention (CDC).
A team of researchers from Roswell Park Comprehensive Cancer Center and the CDC report new evidence that inhalation of vitamin E acetate is strongly linked to e-cigarette, or vaping, product use-associated lung injury (EVALI).
Black men with high blood pressure could benefit from a research study beginning this month to check their vitals while they are getting a haircut at a barbershop.
A Rutgers-led study in JAMA Network Open, found substantial differences between top-cited ob-gyn articles that were published in non-specialty journals compared to those published in ob-gyn journals.
Around the country, the collective voice of eight directors of health workforce research centers came together to call for a reforming of laws and regulations that limit the practice of health professionals. Their commentary was published Feb. 12 in The New England Journal of Medicine.
The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can become much more patient-friendly by using half the typical dose of steroids and no blood plasma exchanges
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in The New England Journal of Medicine.
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Dr. Douglas E. Wood describes the findings from the NELSON Trial and what they mean for policy and program development for lung cancer early detection through CT screening.
Physician-Scientists and other researchers at Rush University Medical Center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of AKI.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.
– Over the past year, at least seven children have died from diseases including influenza while being detained by the U.S. Department of Homeland Security’s Customs and Border Protection (CBP) agency. Infectious disease experts at the University of Maryland School of Medicine (UMSOM) called for protections like influenza vaccinations to prevent serious outbreaks.
The Dutch-Belgian Randomized Lung Cancer Screening Trial, known as the NELSON trial (de Koning et al), published Jan. 29 in NEJM, reconfirms that screening high-risk patients greatly reduces lung cancer deaths. Regulators and physicians should act to ensure access to these lifesaving exams.
University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma (GBM), a deadly Grade IV cancer of the brain.
UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. The original study, which ran from 2012-2017, was published in New England Journal of Medicine in July 2018 as well as highlighted on “60 Minutes” in 2015 and again in 2018. The study found that survival rates were significantly higher in glioblastoma patients who received an intratumoral infusion of a modified viral chimera combining the polio and rhinoviruses (PVSRIPO immunotherapy) compared to patients receiving standard treatment at the same institution.
The results of the B Part of It study – the largest meningococcal B herd immunity study ever conducted – are published today in the New England Journal of Medicine.
Hackensack University Medical Center researchers in Emergency Medicine participated in a nationwide study published in the New England Journal of Medicine in November 2019 that concluded that three drugs are equally safe and effective in treating patients with life-threatening seizures called Status Epilepticus (SE). The new study, Established Status Epilepticus Treatment Trial (ESETT), examined three medications commonly administered in the emergency department to treat SE – levetiracetam, fosphenytoin, and valproate – in order to learn which is most effective in treating patients.
A young boy with a rare genetic disease that typically kills within weeks of birth is now 3 years old and in remission thanks to a collaborative effort that included physicians at King Saud University Department of Pediatrics and immunologists at the Icahn School of Medicine at Mount Sinai.
Moll was the only non-NASA physician NASA consulted when it was discovered that an astronaut aboard the ISS had a deep vein thrombosis (DVT) – or blood clot – in the jugular vein of their neck.
The New England Journal of Medicine review by Mount Sinai experts will serve as a major resource and guide for all physicians looking for best care strategies
A new clinical trial in the emergency department finds no difference in efficacy or adverse effects of three commonly used treatments for patients with refractory status epilepticus.
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.
This new approach applies to D-dimer blood tests, which are used by physicians to rule out the presence of a blood clot.
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
A phase three clinical trial that UT Southwestern participated in determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a single copy of the most common genetic mutation for the disease.
Though identifying data typically are removed from medical image files before they are shared for research, a Mayo Clinic study finds that this may not be enough to protect patient privacy.
A study published today in The New England Journal of Medicine found that in patients seen for heartburn unresponsive to treatment with Proton Pump Inhibitors (PPIs), an extensive, systematic workup revealed truly PPI-refractory and reflux-related heartburn in only a minority of cases. In other words, most patients with heartburn unrelieved by PPIs did not have gastroesophageal reflux disease (GERD) causing the symptom. Furthermore, for the selected subgroup identified as having reflux-related, PPI-refractory heartburn, surgery that corrects reflux was significantly superior (67% success rate) to continued medical therapy (28% success rate).
A multi-center randomized clinical trial evaluating a new artificial pancreas system — which automatically monitors and regulates blood glucose levels — has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes.The study showed that the system improved participants’ blood glucose control throughout the day and overnight.